DK2771037T3 - Terapeutiske midler og anvendelser deraf - Google Patents

Terapeutiske midler og anvendelser deraf Download PDF

Info

Publication number
DK2771037T3
DK2771037T3 DK12798792.3T DK12798792T DK2771037T3 DK 2771037 T3 DK2771037 T3 DK 2771037T3 DK 12798792 T DK12798792 T DK 12798792T DK 2771037 T3 DK2771037 T3 DK 2771037T3
Authority
DK
Denmark
Prior art keywords
agent
antibody
use according
prostate cancer
moiety
Prior art date
Application number
DK12798792.3T
Other languages
English (en)
Inventor
Sven-Erik Strand
Sven-Niklas Anders Axelsson
Amanda Thuy Tran
Original Assignee
Fredax Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fredax Ab filed Critical Fredax Ab
Application granted granted Critical
Publication of DK2771037T3 publication Critical patent/DK2771037T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasonic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)

Claims (23)

1. Middel omfattende eller bestående af (a) et antistof eller antigen-bindende fragment deraf med specificitet for human glandulær kallikrein (hK2) og (b) en cytotoksisk molekyldel, til anvendelse i behandlingen af prostatacancer.
2. Middel til anvendelse ifølge krav 1, hvor antistoffet eller det antigen-bindende fragment deraf med specificitet for hK2 konkurrerer om binding til hK2 med antistof 11 B6, hvor antistof 11 B6 omfatter en tung kæde med en aminosyresekvens med SEQ ID NO: 4 og en let kæde med en aminosyresekvens med SEQ ID NO: 5.
3. Middel til anvendelse ifølge krav 1 eller 2, hvor antistoffet eller det antigenbindende fragment deraf med specificitet for hK2 omfatter én eller flere komplementaritets bestemmende regioner af antistof 11 B6, hvor antistof 11 B6 omfatter en tung kæde med en aminosyresekvens med SEQ ID NO: 4 og en let kæde med en aminosyresekvens med SEQ ID NO: 5.
4. Middel til anvendelse ifølge et hvilket som helst af de foregående krav, hvor midlet omfatter eller består af antistof 11 B6 eller et antigen-bindende fragment deraf, hvor antistof 11 B6 omfatter en tung kæde med en aminosyresekvens med SEQ ID NO: 4 og en let kæde med en aminosyresekvens med SEQ ID NO: 5.
5. Middel til anvendelse ifølge et hvilket som helst af de foregående krav hvor antistoffet eller det antigen-bindende fragment deraf med specificitet for hK2 er bundet indirekte til den cytotoksiske molekyldel.
6. Middel til anvendelse ifølge krav 1, hvor antistoffet eller det antigen-bindende fragment deraf med specificitet for hK2 er bundet direkte til den cytotoksiske molekyldel.
7. Middel til anvendelse ifølge krav 5 eller 6, hvor midlet viser tumoroptagelseskarakteristika i det væsentlige er lig med tumoroptagelseskarakteristika af antistoffet eller det antigen-bindende fragment deraf med specificitet for hK2 alene.
8. Middel til anvendelse ifølge et hvilket som helst af kravene 5-7, hvor den cytotoksiske molekyldel omfatter eller består af én eller flere radioisotoper.
9. Middel til anvendelse ifølge krav 8, hvor den ene eller flere radioisotoper er hver uafhængigt valgt fra gruppen bestående af beta-emittere, Auger-emittere, omdannelses-elektron-emittere, alfa-emittere, og lavfoton-energi-emittere.
10. Middel til anvendelse ifølge krav 8 eller 9, hvor én eller flere radioisotoper hver uafhængigt har et emissionsmønster af lokal absorberet energi der danner høj-dosis-absorbans i nærheden af midlet.
11. Middel til anvendelse ifølge et hvilket som helst af kravene 8 til 10, hvor én eller flere radioisotoper er hver uafhængigt valgt fra gruppen bestående af lavområde beta-emittere, såsom 90Y, 32P, 186Re; 166Ho, 76As/77As, 89Sr, 153Sm; medium-område beta-emittere, såsom 131I, 177Lu, 67Cu, 161Tb, 105Rh; lav-energi-beta-emittere, såsom 45Ca or 35S; omdannelses- eller Auger-emittere, såsom 51Cr, 67Ga, "Tcm, mIn, 114mIn, 1231 1251 201TI; og alfa-emittere, såsom 212Bi 213Bi 223Ac, 225Ac, 212Pb 255Fm 223Ra, 149Tb og 221At.
12. Middel til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den cytotoksiske molekyldel omfatter eller består af én eller flere cytotoksiske lægemidler.
13. Middel til anvendelse ifølge krav 12, hvor den ene eller flere cytotoksiske lægemidler er hver uafhængigt, valgt fra gruppen bestående af et cytostatisk lægemiddel; et anti-androgen lægemiddel; cortison og derivater deraf; et phosphonat; en testosteron-5-a-reduktaseinhibitor; et bor-tilsætningsstof; en cytokin; thapsigargin og dets metabolitter; et toxin (såsom saporin eller calicheamicin); et kemoterapeutisk middel (såsom en antimetabolit); eller hvilket som helst andet cytotoksisk lægemiddel der er anvendeligt i behandlingen af prostatisk carcinom.
14. Middel til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den cytotoksiske molekyldel omfatter eller består af én eller flere molekyldele der er egnede til anvendelse i aktiveringsterapi, såsom fotonaktiveringsterapi, neutronaktiveringsterapi, neutroninduceret Auger-elektronterapi, synchrotron-stråleterapi, eller lav energi røntgen-fotonaktiveringsterapi.
15. Middel til anvendelse ifølge kravene 8 til 11, hvor radioisotopen er i stand til simultant at virke på en multi-modal måde som en detekterbar molekyldel og også som en cytotoksisk molekyldel.
16. Middel til anvendelse ifølge et hvilket som helst af de foregående krav, hvor midlet yderligere omfatter en molekyldel til at øge in vivo halveringstiden af midlet.
17. Middel til anvendelse ifølge krav 16, hvor molekyldelen til at øge in vivo halveringstiden er valgt fra gruppen bestående af polyethylenglycol (PEG), human serumalbumin, glycosyleringsgrupper, fedtsyrer og dextran.
18. Middel til anvendelse ifølge et hvilket som helst af de foregående krav hvor prostatacanceren der skal behandles er ikke-lokaliseret (/'.e., dissemineret) prostatacancer.
19. Middel til anvendelse ifølge et hvilket som helst af de foregående krav, hvor prostatacanceren der skal behandles er metastatisk prostatacancer, eventuelt mikrometastatisk prostatacancer.
20. Middel til anvendelse ifølge krav 19, hvor den metastatiske prostatacancer der skal behandles er metastaser fra lymfesystemet; metastaser fra knogle (herunder rygsøjlen, ryghvirvler, bækken og/eller ribben); metastaser i bækkenet, rektum, blæren og/eller urinrøret.
21. Middel til anvendelse ifølge et hvilket som helst af de foregående krav, hvor patienten har prostatacancer og er yngre end 70, 65, 60, 55, 50, 45, 40 eller færre år gammel ved tidspunktet for diagnose af prostatacancer og/eller ved tidspunktet for behandling.
22. Middel til anvendelse ifølge et hvilket som helst af de foregående krav, hvor patienten er kendetegnet ved at et familiemedlem, såsom en far eller bror, tidligere er blevet diagnosticeret med prostatacancer.
23. Middel til anvendelse ifølge et hvilket som helst af de foregående krav, hvor prostatacanceren der skal behandles er kastrations-modstandsdygtig prostatacancer (CRPC).
DK12798792.3T 2011-10-28 2012-10-26 Terapeutiske midler og anvendelser deraf DK2771037T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552796P 2011-10-28 2011-10-28
PCT/GB2012/052675 WO2013061083A2 (en) 2011-10-28 2012-10-26 Therapeutic agents and uses thereof

Publications (1)

Publication Number Publication Date
DK2771037T3 true DK2771037T3 (da) 2016-11-14

Family

ID=47326213

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12798792.3T DK2771037T3 (da) 2011-10-28 2012-10-26 Terapeutiske midler og anvendelser deraf

Country Status (18)

Country Link
US (5) US9345782B2 (da)
EP (1) EP2771037B1 (da)
JP (1) JP6101274B2 (da)
KR (2) KR102232811B1 (da)
CN (1) CN104159618B (da)
AU (1) AU2012328173B2 (da)
BR (1) BR112014010739A2 (da)
CA (1) CA2853669C (da)
DK (1) DK2771037T3 (da)
ES (1) ES2601459T3 (da)
IL (1) IL232262A (da)
LT (1) LT2771037T (da)
MX (1) MX353964B (da)
PL (1) PL2771037T3 (da)
PT (1) PT2771037T (da)
RU (1) RU2606773C2 (da)
WO (1) WO2013061083A2 (da)
ZA (1) ZA201403372B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013061083A2 (en) 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
MY193914A (en) 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
SMT201900338T1 (it) * 2013-11-19 2019-07-11 Fredax Ab Anticopri anti-callicreina-2 umanizzato
GB2520353A (en) * 2013-11-19 2015-05-20 Fredax Ab Antibody polypeptides and uses thereof
DK3123381T3 (da) 2014-03-28 2023-11-27 Opko Diagnostics Llc Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3154587B1 (en) 2014-06-13 2020-01-15 Tenboron OY Conjugates comprising an anti-egfr1 antibody
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
CN108136013B (zh) * 2015-10-05 2023-04-18 弗雷达克斯有限责任公司 抗体多肽及其用途
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
US10183041B2 (en) * 2017-04-12 2019-01-22 Vector Vitale Ip Llc Antibacterial composition and its use in treating bacterial infections
DE202017006951U1 (de) 2017-08-14 2019-02-07 Opko Diagnostics, Llc Multiplex-Assays zur Beurteilung des Prostatakrebsstatus
JP7339692B2 (ja) * 2019-03-29 2023-09-06 国立研究開発法人量子科学技術研究開発機構 放射性標識化合物の製造方法及び製造装置
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
CN112294760B (zh) * 2019-07-26 2025-12-12 宁波新致生物科技有限公司 一种液体制剂及其应用
AU2020322221A1 (en) 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)
CN112295112A (zh) * 2019-07-31 2021-02-02 广州康近医疗技术有限公司 前列腺癌β粒子腔内治疗机
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
WO2025034663A2 (en) * 2023-08-04 2025-02-13 The General Hospital Corporation Differentiation of patients with and without prostate cancer using urine 1h nmr metabolomics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6379669B1 (en) * 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CN1238013A (zh) 1996-11-14 1999-12-08 梅奥医学教育及研究基金会 转移性前列腺癌的检测方法
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
WO2001012218A1 (en) 1999-08-16 2001-02-22 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
FI20002127A0 (fi) * 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20040219163A1 (en) 2001-10-03 2004-11-04 Frelinger John G. Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
EP2347767A3 (en) * 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
US7492512B2 (en) 2004-07-23 2009-02-17 Mirage International Ltd. Wide field-of-view binocular device, system and kit
US8663600B2 (en) * 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
KR100723009B1 (ko) 2005-11-30 2007-05-29 한국원자력연구원 인간 ｐ３１ 유전자를 함유하는 악성 종양 치료용 약학적조성물
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
WO2013061083A2 (en) 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
SMT201900338T1 (it) 2013-11-19 2019-07-11 Fredax Ab Anticopri anti-callicreina-2 umanizzato

Also Published As

Publication number Publication date
RU2014121499A (ru) 2015-12-10
IL232262A0 (en) 2014-06-30
HK1201454A1 (en) 2015-09-04
ZA201403372B (en) 2017-08-30
IL232262A (en) 2016-08-31
MX353964B (es) 2018-02-06
US9345782B2 (en) 2016-05-24
KR20210036987A (ko) 2021-04-05
PT2771037T (pt) 2016-11-08
JP2014530898A (ja) 2014-11-20
CA2853669C (en) 2019-03-12
MX2014005143A (es) 2014-11-25
KR20140085569A (ko) 2014-07-07
CA2853669A1 (en) 2013-05-02
BR112014010739A2 (pt) 2017-04-25
KR102362358B1 (ko) 2022-02-15
US12383637B2 (en) 2025-08-12
JP6101274B2 (ja) 2017-03-22
EP2771037B1 (en) 2016-08-03
PL2771037T3 (pl) 2017-06-30
US20200138986A1 (en) 2020-05-07
CN104159618A (zh) 2014-11-19
RU2606773C2 (ru) 2017-01-10
US20140286862A1 (en) 2014-09-25
KR102232811B1 (ko) 2021-03-29
AU2012328173A1 (en) 2014-05-29
AU2012328173B2 (en) 2016-04-21
CN104159618B (zh) 2018-06-01
US20260048159A1 (en) 2026-02-19
US20220125961A1 (en) 2022-04-28
WO2013061083A2 (en) 2013-05-02
US20160317683A1 (en) 2016-11-03
WO2013061083A3 (en) 2013-06-27
ES2601459T3 (es) 2017-02-15
EP2771037A2 (en) 2014-09-03
LT2771037T (lt) 2017-01-25

Similar Documents

Publication Publication Date Title
US12383637B2 (en) Therapeutic agents and uses thereof
US12404343B2 (en) Humanised anti kallikrein-2 antibody
US12441808B2 (en) Antibody polypeptides and uses thereof
HK1201454B (en) Therapeutic agents and uses thereof
BR122022010169B1 (pt) Agentes terapêuticos para uso no tratamento de câncer de próstata e composição farmacêutica
HK1258674B (en) Humanized anti psa (5a10) antibodies